A Phase 1 Study Assessing Local Cutaneous Effects of SB204
NCT ID: NCT02250430
Last Updated: 2018-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
8 participants
INTERVENTIONAL
2014-09-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
P3 Long Term Safety Study of Once Daily SB204 in Acne
NCT02798120
P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
NCT02242760
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
NCT01844739
Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris
NCT02801903
A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris
NCT02164084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topical SB204
Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
SB204
Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB204
Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subject with known sensitivity to a component of the test materials
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novan, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stuart Lessin, MD
Role: PRINCIPAL_INVESTIGATOR
KGL, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KGL
Broomall, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NI-AC102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.